Indegene Peer Comparison
NSE: INDGN | BSE: 544172
₹578.95
₹11.60
(2.04%)
As on 28-Aug-2026IST
Market cap
₹13,940 Cr
Revenue (TTM)
₹3,813 Cr
P/E Ratio
34.8
P/B Ratio
4.3
Div. Yield
0.4 %
Edit
| Indegene | Sai Life Sciences | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
13,940 | 31,434 | 14,932 | 9,704 | 2,746 |
Revenue (₹ Cr) |
3,813 | 2,250 | 3,172 | 950 | 2,901 |
Net Profit (₹ Cr) |
400.90 | 361.74 | 521.27 | 266.00 | 16.16 |
Net Margin (%) |
10.30 | 15.77 | 15.92 | 27.44 | 0.55 |
RoE (%) |
13.87 | 15.47 | 18.10 | 72.69 | 0.29 |
Price to Earnings |
34.77 | 86.90 | 28.90 | 36.48 | 169.93 |
Price-To-Book |
4.34 | 12.31 | 4.70 | 27.89 | 0.41 |
Income Statement (₹ Cr)
| Indegene | Sai Life Sciences | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Operating Revenue
|
3,510.50 | 2,192.49 | 2,950.94 | 878.40 | 2,711.50 |
|
Total Income
|
3,582.50 | 2,266.90 | 3,033.47 | 896.80 | 2,762.39 |
|
Total Expenditure
|
2,891.50 | 1,584.97 | 2,350.16 | 569.40 | 2,271.77 |
|
EBITDA
|
619.00 | 607.53 | 600.78 | 309.00 | 439.73 |
|
Depreciation
|
126.40 | 166.86 | 98.63 | 11.70 | 293.74 |
|
EBIT
|
492.60 | 440.67 | 502.15 | 297.30 | 145.99 |
|
Interest
|
19.30 | 40.88 | 24.13 | 2.00 | 159.46 |
|
Other Income
|
72.00 | 74.40 | 82.53 | 18.40 | 50.89 |
|
Exceptional Items
|
-20.30 | -8.00 | -- | 6.60 | -18.11 |
|
Profit before Tax
|
525.00 | 466.19 | 560.56 | 320.30 | 19.31 |
|
Provision for Tax
|
123.90 | 117.28 | 140.49 | 80.20 | 16.07 |
|
Profit after Tax
|
401.10 | 348.91 | 420.06 | 240.10 | 3.24 |
Liabilities (₹ Cr)
| Indegene | Sai Life Sciences | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
3,138.70 | 2,483.69 | 3,023.16 | 384.00 | 5,831.52 |
|
Minority Interest
|
-- | -- | 29.52 | -- | -- |
|
Non-Current Liabilities
|
318.60 | 321.65 | 268.17 | 229.90 | 2,230.03 |
|
Current Liabilities
|
1,086.20 | 904.59 | 527.09 | 128.40 | 1,924.79 |
|
Total Liabilities
|
4,620.30 | 3,709.93 | 3,855.82 | 750.80 | 9,986.90 |
Assets (₹ Cr)
| Indegene | Sai Life Sciences | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,925.10 | 2,228.49 | 1,125.20 | 248.00 | 7,785.92 |
|
Current Assets
|
2,618.40 | 1,481.44 | 2,722.74 | 494.30 | 2,200.42 |
|
Total Assets
|
4,620.30 | 3,709.93 | 3,855.82 | 750.80 | 9,986.90 |
|
Total Debt*
|
0.00 | 95.13 | 29.59 | 0.00 | 2,083.91 |
|
Net Current Assets
|
1,532.20 | 576.85 | 2,195.65 | 365.90 | 275.63 |
|
Contingent Liabilities
|
-- | 97.31 | -- | 1.50 | 423.42 |
Cashflow (₹ Cr)
| Indegene | Sai Life Sciences | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
650.80 | 509.13 | 458.13 | 174.80 | 375.23 |
|
Cash Flow from Investing Activities
|
-512.40 | -395.41 | -248.27 | 7.60 | -192.21 |
|
Cash from Financing Activities
|
-82.60 | -123.68 | -70.93 | -134.50 | -102.09 |
|
Net Cash Inflow / Outflow
|
55.80 | -9.96 | 138.93 | 47.90 | 80.93 |
Ratios
Profitability Ratios
| Indegene | Sai Life Sciences | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
ROCE (%)
|
18.92 | 20.97 | 21.10 | 98.11 | 2.31 |
|
ROE (%)
|
14.14 | 15.16 | 15.31 | 73.20 | 0.06 |
|
ROA (%)
|
10.31 | 10.09 | 11.85 | 37.26 | 0.03 |
|
EBIT Margin (%)
|
19.68 | 31.10 | 23.16 | 37.27 | 18.09 |
|
Net Margin (%)
|
11.20 | 15.39 | 13.85 | 26.77 | 0.12 |
|
Cash Profit Margin (%)
|
15.03 | 23.50 | 17.07 | 27.35 | 10.95 |
Growth Ratios
| Indegene | Sai Life Sciences | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
23.64 | 29.38 | 12.51 | 21.24 | 3.66 |
|
EBIT Growth (%)
|
7.72 | 53.37 | 14.07 | 15.44 | 55.90 |
|
Net Profit Growth (%)
|
-1.38 | 105.08 | 9.79 | 32.65 | 102.11 |
|
EPS Growth (%)
|
-1.79 | 101.82 | 9.81 | 32.65 | 102.11 |
|
Book Value Growth (%)
|
19.89 | 16.76 | 22.41 | 41.18 | 3.63 |
Valuation Ratios
| Indegene | Sai Life Sciences | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Price / Earnings
|
26.06 | 58.91 | 17.04 | 43.36 | 1,053.24 |
|
Price / Book Value
|
3.38 | 8.29 | 2.36 | 27.11 | 0.59 |
|
Dividend Yield (%)
|
0.52 | 0.00 | 0.57 | 1.66 | 0.00 |
|
EV/EBITDA
|
14.57 | 30.12 | 9.02 | 30.65 | 10.17 |
|
Market Cap (₹ Cr)
|
10,450.76 | 20,554.39 | 7,121.50 | 10,410.62 | 3,411.88 |
Solvency Ratios
| Indegene | Sai Life Sciences | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.04 | 0.01 | 0.00 | 0.36 |
|
Short term debt to equity ratio
|
-- | 0.03 | 0.01 | -- | 0.11 |
|
Current Ratio
|
2.41 | 1.64 | 5.17 | 3.85 | 1.14 |
|
Quick Ratio
|
2.41 | 1.47 | 3.32 | 3.37 | 0.68 |
|
Interest Coverage
|
28.20 | 12.40 | 24.24 | 161.15 | 1.12 |
Operating Efficiency Ratios
| Indegene | Sai Life Sciences | Marksans Pharma | Sanofi Consumer Healthcare India | Dishman Carbogen | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
27.97 | 17.04 | 21.84 | 3.37 | 24.53 |
|
Asset Turnover
|
0.90 | 0.63 | 0.86 | 1.43 | 0.28 |
|
Receivable days
|
90.10 | 60.56 | 71.16 | 8.58 | 77.38 |
|
Inventory Days
|
0.00 | 22.43 | 109.20 | 20.38 | 120.02 |
|
Payable days
|
-- | 194.31 | 91.82 | 118.89 | 172.74 |
|
Cash Conversion Cycle
|
-- | -111.32 | 88.55 | -89.93 | 24.66 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
